Riskpilot← Back to searchSign inGet full accessBiopart Holding AB
ABActiveOrg 5591461339Sundstavägen 20Activities of holding companies · NACE 6421Est. 20180 employees
Revenue 2024
SEK 0
EBITDA margin
—
0% vs 2023
Equity ratio
60.3%
Financial strength
Net profit 2024
SEK -6K
-101% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -6K | +0% |
| Net profit | SEK -6K | -101% |
| Total assets | SEK 1,1M | -9% |
| Equity | SEK 665K | -1% |
| Employees | 0 | — |
Legal name
Biopart Holding AB
Org number
5591461339
Legal form
Aktiebolag
NACE code
6421 · Activities of holding companies
Founded
22 januari 2018
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är att äga och förvalta aktier och andelar i dotter- och intressebolag, äga och förvalta fast och lös egendom samt bedriva värdepappersförvaltning och därmed förenlig verksamhet.
Address
Sundstavägen 20
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −12 | −6 | −6 | −6 | −6 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | −12 | −6 | −6 | −6 | −6 |
| Net financials | — | — | −0 | 634 | — |
| Profit before tax | −12 | −6 | −6 | 628 | −6 |
| Tax | −0 | −0 | — | — | — |
| Net profit | −12 | −6 | −6 | 628 | −6 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 37 | 930 | 900 | 1 218 | 1 103 |
| Equity | 27 | 50 | 44 | 672 | 665 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 10 | 880 | 856 | 546 | 437 |
| Total debt | 10 | 880 | 856 | 546 | 437 |
EBITDA margin
-625000.0%
This company
15.8%
Market median
-3955796% vs market
20202024
Equity ratio
60.3%
This company
38.2%
Market median
+58% vs market
20202024
Return on equity
-0.9%
This company
18.4%
Market median
-105% vs market
20202024
Net profit margin
-625000.0%
This company
8.1%
Market median
-7716149% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.66×
This company
0.62×
Market median
+6% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
ET Audit | Audit | 2022 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2020 | |
| Deputy Board Member | 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Biopart Holding AB 
Biopart ABBoard members of Biopart Holding AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Erik Tomas Haglund | Audit | 0 companies |
| Hans Per Ulvebring | Board of Directors | 0 companies |
| Hans Bertil Ulvebring | Deputy Board Member | 0 companies |